Genetic link to placebo response in depression

by Anil Kumar



In people suffering from major depressive disorder, depression or MDD, genes that influence the brain's reward pathways may modulate the response to placebos, revealed by researchers.

Research is conducted by Dr. Andrew Leuchter, a professor of psychiatry at the UCLA Semel Institute for Neuroscience and Human Behavior, and published in the August edition of the Journal of Clinical Psychopharmacology.

Placebos are thought to act by stimulating the brain's central reward pathways by releasing a class of neurotransmitters called monoamines, specifically dopamine and norepinephrine. These are the brain chemicals that make us "feel good." Because the chemical signaling done by monoamines is under strong genetic control, the scientists reasoned that common genetic variations between individuals - called genetic polymorphisms - could influence the placebo response.

Researchers took blood samples from 84 people diagnosed with MDD; 32 were given medication and 52 a placebo. The researchers looked at the polymorphisms in genes that coded for two enzymes that regulate monoamine levels: catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAO-A). Subjects with the highest enzyme activity within the MAO-A polymorphism had a significantly lower placebo response than those with other genotypes. With respect to COMT, those with lower enzyme activity within this polymorphism had a lower placebo response.

"Our findings suggest that patients with MDD who have specific MAO-A and COMT genotypes may be biologically advantaged or disadvantaged in mounting a placebo response, because of the activity of these two enzymes," said Leuchter, who directs the Laboratory of Brain, Behavior and Pharmacology at the UCLA Semel Institute.

"To our knowledge, this is the first study to examine the association between MAO-A and COMT polymorphisms and a response to placebo in people who suffer from major depressive disorder," he said.

Leuchter noted that this is not the sole explanation for a response to a placebo, which is likely to be caused by many factors, both biological and psychosocial. "But the data suggests that individual differences in response to placebo are significantly influenced by individual genotypes," he said.

Including the influence of genotype in the design of clinical trials could facilitate more powerful testing of future treatments, Leuchter said.


(Anil Kumar -- sub-editor compiled and published Genetic link to placebo response in depression at HealthNewsTrack on July 22, 2009 sourced from University of California, Los Angeles - http://www.ucla.edu/)

Depression - recent articles and current news stories:

- Working overtime work may lead to depression
- Depression uncouples brain's hate circuit
- Coffee decreases depression in women
- Depression increases stroke and stroke related health problems
- Depression linked to 29% increased risk of stroke in women

Depression article/news source:

Read more health articles from University of California, Los Angeles and health articles from USA.

Depression - search related terms:

Depression, Depressive disorder, Genes, Genetic, Genotype, Human Behavior, Neuroscience, Placebo, Psychopharmacology,
Depression books,

Subscribe to Health News by Email

List health news, Health organizations, Health news world, Glossary, Best health articles, Featured     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2007, 2008, 2009, 2010, 2011 HealthNewsTrack.com
6.59